Moderna Stock News

Analysts expect Moderna’s earnings to be $8.62 per share when they release Q4 earnings results on Thursday, Feb 24.

Moderna Inc (NASDAQ: MRNA ) has entered into a long-term agreement with Thermo Fisher Scientific Inc (NYSE: TMO ) to manufacture its COVID-19 vaccine and other experimental medicines based on mRNA technology. Thermo Fisher had already partnered with Moderna last year to help scale up production of its COVID vaccine, … Full story available on Benzinga.com

The post CDC says waiting longer between Pfizer, Moderna doses may reduce myocarditis risk appeared on BitcoinEthereumNews.com . A healthcare worker prepares a dose of the Pfizer-BioNTech Covid-19 vaccine at a vaccination clinic in the Peabody Institute Library in Peabody, Massachusetts, on Wednesday, Jan. 26, 2022. Vanessa Leroy…

Moderna (NASDAQ:MRNA) is scheduled to announce Q4 earnings results on Thursday, February 24th, before market open.The consensus EPS Estimate is $9.81 (+1521.7% Y/Y) and the

The stock is trying to settle below the $136 level.

Sanofi and GlaxoSmithKline plan to submit their long-awaited Covid-19 vaccine for regulatory approval. Data suggest it''s a contender against Pfizer and Moderna boosters.

The drug maker is rapidly approaching fair value after two years of intense volatility.

Analysts and brokerage firms often use ratings when they issue stock recommendations to stock traders. Analysts arrive at stock ratings by researching public financial statements, communicating with executives and customers and following industry trends. Here are the latest analyst rating updates for Coinbase Global Inc (NASDAQ: COIN ), Moderna Inc (NASDAQ: MRNA ) and Sunnova Energy International Inc (NYSE: NOVA ): The latest price target for Coinbase was by Goldman Sachs on Jan. 26. The analyst firm set a price target for $288, a possible 62.93% upside. Full story available on Benzinga.com

Moderna Inc has entered into a long-term agreement with Thermo Fisher Scientific for the manufacturing of its COVID-19 vaccine and other experimental medicines based on mRNA technology, the companies said on Wednesday.

Moderna (MRNA) reports Q4 earnings before market open on Feb. 24. Can it keep posting healthy profits and revenue on demand for its COVID-19 vaccine?

Moderna (MRNA) and Thermo Fisher Scientific (TMO) have inked a 15-year strategic collaboration agreement. Read more on its details.

Moderna Inc. and life-sciences company Thermo Fisher Scientific Inc. said Wednesday they have entered a long-term agreement to collaborate on large-scale manufacturing of the former''s COVID-19 vaccine dubbed Spikevax and other therapies based on its mRNA technology. In a joint statement, the companies said they have already been working together to support Moderna''s pipeline with Thermo Fisher providing clinical research and contract manufacturing services, including aseptic fill-finish services and packaging of the COVID vaccine. The expanded agreement will see them offer capacity for other fill-finish services and provide inspection, labeling and final packaging services. Moderna shares were up 1.6% premarket, while Thermo Fisher shares were not yet active. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

Osagie Ehanire, Minister for Health, has expressed concern that the number of Nigerians who have been fully vaccinated is still very low because the country has been administering double dose vaccines. The minister decried that most persons who have received their first dose are reluctant to take their second dose for various reasons including fear of a repeat of the mild side effects they may have experienced with the first dose. The minister raised this concern during the launch of SCALES 2.0 strategy, which stands for Service delivery, Communication, Accountability, Logistics, Electronic Reporting, and Supportive Supervision to scale up COVID-19 vaccination organised by the National Primary Health Care Development Agency (NPHCDA). Ehanire disclosed that as of 18th February, Nigeria has administered over 20million doses, representing over 18 percent of the 111,176,503 eligible population targeted for COVID-19 vaccination. THE minister, however, assured that the federal government have over 30 million doses of teh Johnson and Johnson vaccine stock, which is a single-dose vaccine and urged Nigerians to show up for vaccination.

Moderna''s phase 2 trial data for its flu vaccine is expected early this year and could push the stock higher.

Moderna (MRNA) signed a distribution service agreement with privately held Adium Pharma to support the commercialization of its COVID-19 vaccine Spikevax across Latin America.The